Naturally Occurring PCSK9 Inhibitors
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Genetic, epidemiological and pharmacological data have led to the conclusion that antagonizing or inhibiting Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces cardiovascular events. This clinical outcome is mainly related to the pivotal role of PCSK9 in controlling low-density lipoprotein (LDL) cholesterol levels. The absence of oral and affordable anti-PCSK9 medications has limited the beneficial effects of this new therapeutic option. A possible breakthrough in this field may come from the discovery of new naturally occurring PCSK9 inhibitors as a starting point for the development of oral, small molecules, to be used in combination with statins in order to increase the percentage of patients reaching their LDL-cholesterol target levels. In the present review, we have summarized the current knowledge on natural compounds or extracts that have shown an inhibitory effect on PCSK9, either in experimental or clinical settings. When available, the pharmacodynamic and pharmacokinetic profiles of the listed compounds are described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Del Rio, D., Rodriguez-Mateos, A., Spencer, J. P. E., Tognolini, M., Borges, G., & Crozier, A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4581 · Cited by 2,601
The Essential Medicinal Chemistry of Curcumin
Nelson, K. M., Dahlin, J. L., Bisson, J., Graham, J., Pauli, G. F., & Walters, M. A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00975 · Cited by 1,956 · cited 1×
“In particular, curcumin presents a poor stability under physiological conditions, with a t1/2 of less than 10 min [127].”
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Carotenoid radical chemistry and antioxidant/pro-oxidant properties
El-Agamey, A., Lowe, G. M., McGarvey, D. J., Mortensen, A., Phillip, D. M., Truscott, T. G., & Young, A. J. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.03.007 · Cited by 627
Health benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523
The chemistry and biotransformation of tea constituents
Sang, S., Lambert, J. D., Ho, C.-T., & Yang, C. S. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.02.007 · Cited by 492 · cited 1×
“The reason for such variability is the high rate of metabolism: ECGC is mainly biotransformed in the liver and in the small intestine, leading to methylated, sulfated and glucuronidated metabolites, as well as phenylvalerolactones and phenylvaleric acids, that successively undergo glucuronidation [85,96,97].”
Bjermo, H., Iggman, D., Kullberg, J., Dahlman, I., Johansson, L., Persson, L., Berglund, J., Pulkki, K., Basu, S., Uusitupa, M., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.030114 · Cited by 490 · cited 1×
“With respect to the mechanism underlying the relationship between omega-3 and PCSK9, it has been hypothesized to be a modulation of SREBP2-mediated pathways [171].”
Lan, J., Zhao, Y., Dong, F., Yan, Z., Zheng, W., Fan, J., & Sun, G. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.09.049 · Cited by 458 · cited 2×
“This variation was accompanied by a significant reduction in TG levels and a modest increase, albeit significant, of HDL-cholesterol levels [13,14,31].”
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407 · cited 1×
“With respect to cholesterol metabolism, EPA and DHA have been shown to reduce production, and may induce a faster clearance of triglyceride-rich lipoproteins (TGRL), with a paralleled more rapid clearance of LDL particles and slower production of VLDL particles [160].”
Ras, R. T., Geleijnse, J. M., & Trautwein, E. A. (2014) · British Journal of Nutrition · doi:10.1017/s0007114514000750 · Cited by 379 · cited 1×
“Among available dietary supplements/substituents for cholesterol reduction, plant sterols/stanols have one of the widest uses [44].”
Liu, Y.-T., Hao, H.-P., Xie, H.-G., Lai, L., Wang, Q., Liu, C.-X., & Wang, G.-J. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.033936 · Cited by 356 · cited 3×
“Berberine phase I metabolites M1 via demethylation, M2 via demethylenation, and M3 (jatrorrhizine), from which derive phase II metabolites that are the corresponding glucuronide conjugates of M1, M2, and M3, respectively [23].”
Guo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J.-L., Green, B., Deng, H., Kaput, J., & Ning, B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035873 · Cited by 348
Quercetin pharmacokinetics in humans
Moon, Y. J., Wang, L., DiCenzo, R., & Morris, M. E. (2008) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.605 · Cited by 287 · cited 1×
“1 Liver: Sulfate and methyl glucuronide; Gut microbiota: free aglycone; 3,4dihydroxyphenylaceti c acid, 3-(3hydroxyphenyl) propionic acid, 3,4dihydroxybenzoic acid and 4hydroxybenzoic acid Inhibits secretion (sortilin) and SREBP P-gp sand BCRP In vitro and in vivo Not known [72,73] [78,80,81]”
The Role of Nutraceuticals in Statin Intolerant Patients
Banach, M., Patti, A. M., Giglio, R. V., Cicero, A. F. G., Atanasov, A. G., Bajraktari, G., Bruckert, E., Descamps, O., Djuric, D. M., Ezhov, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.040 · Cited by 272
Allaire, J., Couture, P., Leclerc, M., Charest, A., Marin, J., Lépine, M.-C., Talbot, D., Tchernof, A., & Lamarche, B. (2016) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.131896 · Cited by 252 · cited 12×
“Allaire et al. also observed that the responders to DHA or to EPA, in terms of TG reduction, had greater serum PCSK9 concentration at baseline than nonresponders, suggesting a modulatory role of this protein in the n-3 PUFA-mediated effects [170].”
InfluentialWesterink, W. M. A., & Schoonen, W. G. E. J. (2007) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.06.017 · Cited by 226
Berberine in the treatment of type 2 diabetes mellitus: A systemic review and meta-analysis
Dong, H., Wang, N., Zhao, L., & Lu, F. (2012) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2012/591654 · Cited by 225
TANG, Z., JIANG, L., PENG, J., REN, Z., WEI, D., WU, C., PAN, L., JIANG, Z., & LIU, L. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1072 · Cited by 208
Dong, H., Zhao, Y., Zhao, L., & Lu, F. (2013) · Planta Medica · doi:10.1055/s-0032-1328321 · Cited by 171
Repeated administration of berberine inhibits cytochromes P450 in humans
Guo, Y., Chen, Y., Tan, Z.-R., Klaassen, C. D., & Zhou, H.-H. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1108-2 · Cited by 137
Poli, A., Barbagallo, C. M., Cicero, A. F. G., Corsini, A., Manzato, E., Trimarco, B., Bernini, F., Visioli, F., Bianchi, A., Canzone, G., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.05.015 · Cited by 134
Mukuddem-Petersen, J., Stonehouse (Oosthuizen), W., Jerling, J. C., Hanekom, S. M., & White, Z. (2007) · British Journal Of Nutrition · doi:10.1017/s0007114507682944 · Cited by 131
Regulation of PCSK9 by nutraceuticals
Momtazi, A. A., Banach, M., Pirro, M., Katsiki, N., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.023 · Cited by 131
Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages
Adorni, M. P., Cipollari, E., Favari, E., Zanotti, I., Zimetti, F., Corsini, A., Ricci, C., Bernini, F., & Ferri, N. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.11.019 · Cited by 130 · cited 1×
“This may unravel a direct antiatherogenic and LDL-cholesterol-independent effect of quercetin, since PCSK9 negatively modulates cholesterol metabolism and inflammation in macrophages [75,76].”
Self-citationP-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers
Maeng, H.-J., Yoo, H.-J., Kim, I.-W., Song, I.-S., Chung, S.-J., & Shim, C.-K. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10268 · Cited by 128
Lipid lowering therapy and circulating PCSK9 concentration
Nozue, T. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17012 · Cited by 127 · cited 1×
“Interestingly, curcumin almost completely abrogated the PCSK9-inducing effect of lovastatin, suggesting that curcumin could counteract the effect of statin on circulating PCSK9 [123] and opening new perspectives on novel nutraceutical cholesterol-lowering combination approaches (Figure 1).”
Horton, J. D., Cuthbert, J. A., & Spady, D. K. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116645 · Cited by 100 · cited 1×
“This animal model was chosen since the kinetics of hepatic LDLR-mediated LDL clearance have been well characterized [27].”
Tabrizi, R., Tamtaji, O. R., Mirhosseini, N., Lankarani, K. B., Akbari, M., Heydari, S. T., Dadgostar, E., & Asemi, Z. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2019.1604491 · Cited by 88 · cited 1×
“As example, quercetin supplementation has shown to reduce by approximately 12% LDL-C levels, as emerged from a recent meta-analysis of randomized controlled trials [79].”
Pisciotta, L., Bellocchio, A., & Bertolini, S. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-123 · Cited by 79
Wang, L., Ye, X., Hua, Y., & Song, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.110 · Cited by 59
Cited by
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sundararaman, S. S., Döring, Y., & van der Vorst, E. P. C. (2021) · Biomedicines · doi:10.3390/biomedicines9070793 · Cited by 67
PCSK9 in metabolism and diseases
Ajoolabady, A., Pratico, D., Mazidi, M., Davies, I. G., Lip, G. Y. H., Seidah, N., Libby, P., Kroemer, G., & Ren, J. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156064 · Cited by 49
Okoro, E. U. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126236 · Cited by 18
Research on Hepatocyte Regulation of PCSK9-LDLR and Its Related Drug Targets
Liu, S.-S., Yu, T., Qiao, Y.-F., Gu, S.-X., & Chai, X.-L. (2024) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-023-3545-z · Cited by 11
“(39) HNF-1 α promotes PCSK9 transcription by binding with HNF1 motif, which is located at upstream of SRE1 in PCSK9 promoter.”
Metadata
- Authors
- Adorni, M. P., Zimetti, F., Lupo, M. G., Ruscica, M., & Ferri, N.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2020-05-16
- Volume
- 12
- Issue
- 5
- Pages
- 1440
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W3025949713
- Cited by
- 92
- References
- 36
- FWCI
- 9.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.